Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

rganism from synthesizing proteins. Methionyl tRNA synthetase is a novel target that has not been previously exploited by antibiotics and REP3123 shows no cross-resistance to currently marketed antibacterial agents. To determine the ability of REP3123 to prevent sporulation of C. difficile, four clinical isolates were studied including two epidemic BI/NAP1/027 strains identified in recent outbreaks in Quebec, Canada. The BI/NAP1/027 outbreak strains produce greater amounts of toxins A and B, have increased sporulation capacity, and cause more severe disease and increased morbidity and mortality. All bacterial strains were grown in the presence of low concentrations (sub-minimum inhibitory concentrations or MICs) of either REP3123, vancomycin or metronidazole. Spores were quantified after 96 hours of drug exposure. All four strains of C. difficile varied in their ability to produce spores under the conditions evaluated in this study. At 0.5 times the MIC, REP3123 was the most effective agent at preventing the production of spores in all strains (equal to or less than 1% of spores after 96 hours of treatment). In contrast, sub-MICs of metronidazole promoted spore formation in three strains and vancomycin promoted sporulation in two strains. The ability of REP3123 to inhibit sporulation was concentration-dependent, with no spores detected at concentrations of 0.5 times the MIC. The FDA has not approved REP3123 for marketing in this or any other indication.

"CDAD is a challenging disease for many reasons, including the difficulty associated with eradication of Clostridium difficile and its spores from the environment," explained Stuart Johnson, M.D., Associate Professor of Medicine, Stritch School of Medicine, Loyola University and the Hines VA Medical Center in Chicago. "These results demonstrating that REP3123 has a direct impact on inhibiting spore-formation of C. difficile bacteria are highly promising and clinically relevant."

"Through a novel mechanism
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CITY, Calif., Aug. 3, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... business update and reported financial results for the three ... Business highlights include: , On July 23, 2015, ... adopted a positive opinion for Zalviso™ for the management ...
(Date:8/3/2015)... August 3, 2015 ReportsnReports.com ... research with 2020 forecasts as well as Global ... medical devices intelligence collection of its library. ... with 2020 forecasts spread across 164 pages, talking ... tables and figures is now available at ...
(Date:8/3/2015)... 3, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... plc,s (NASDAQ: HZNP ) ("Horizon") announcement that it ... Board") set a record date to determine the shareholders ... The Depomed Board will review the request when it ... and contains the information required under Depomed,s bylaws, the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6
... Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be presenting ... 31st Annual Cowen and Company Healthcare Conference on Tuesday, March ... presenting at 10:15 AM (EST). Barclays Capital 2011 Global ... Hotel, Miami, FL, presenting at 10:15 AM (EDT). ...
... SPRING, Md., March 4, 2011 New data suggest ... increase the risk for the birth defects cleft lip ... use the medication during pregnancy, the U.S. Food and ... ) Before prescribing topiramate, approved to treat ...
Cached Medicine Technology:FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate 2FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate 3
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently ... small, medium, and large businesses making an impact in their industry. Andrew Tropeano, the ... how the famous hot dog maker now offers a 50% Reduced Fat All-Beef ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA and the program's ... depression. Depression affects millions of Americans every single year. To help people obtain ... viewers with the latest segment produced with the assistance of several top medical ...
(Date:8/4/2015)... KS (PRWEB) , ... August 04, 2015 , ... ... today their partnership to make the Isabel Symptom Checker available to all users ... consumers a mechanism to check their symptoms in an easy, intuitive method, provides ...
(Date:8/3/2015)... ... 04, 2015 , ... Keeping strong to their ongoing commitment ... today announced extra savings on Florida Physical Therapy continuing education packages. ... on Physical Therapy Flex packages by entering the promo code "FL229" ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:Elite Online CE Provider Offers Discounted Flexible Packages to Meet Florida Physical Therapy Continuing Education Requirements 2
... Iron Mountain to Host Free Webcast on Making a Smooth ... Iron Mountain Incorporated (NYSE: IRM ), the ... Exempla Healthcare, will share tips during an upcoming Webcast for ... (EMR). , , In this free, hour-long Webcast, attendees ...
... Va., June 4 GTSI Corp.(R) (Nasdaq: ... services provider to government and healthcare organizations, today announced ... 2009 Technology Leadership Series seminar. Entitled, "Let,s Talk ... the seminar will feature industry-leading experts and healthcare providers. ...
... 30 seconds of ringtone linked to 25% drop in test ... As if folks needed another reason to be annoyed at ... seconds of a stranger,s nearby ringtone can impair thinking, at ... saw their test scores sink after a fellow "student,s" phone ...
... five therapeutic areas , , Expanding indications for strong ... global capabilities and reach drives growth efforts in emerging markets , ... medicine , , Company,s vision focuses on improving human ... BRUNSWICK, N.J., June 4 Johnson & Johnson (NYSE: ...
... , , , Proven Interoperability ... Hologic, Kodak Carestream, Intergy RIS, Cloverleaf, Meditech RIS, ... CHARLOTTE, N.C., June 4 Healthcare IT workflow ... generation of its comprehensive suite of Enterprise digital ...
... was released today by 1st Class Kids: , ... to raise money in support of continued obesity research ... with TopGolf Skills Challenges, game play, live entertainment, information ... need to raise awareness about childhood obesity. Additionally, there ...
Cached Medicine News:Health News:Best Practices for Hospitals Moving to Electronic Medical Records 2Health News:GTSI to Spotlight Key Trends in Health IT at its June 17 Technology Leadership Series Seminar 2Health News:GTSI to Spotlight Key Trends in Health IT at its June 17 Technology Leadership Series Seminar 3Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 3Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 2Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 3Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 4Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 5Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 6Health News:Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs 7Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 2Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 3Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 4
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... Mononucleosis test is designed to detect ... plasma or whole blood. The QuickVue+ ... of bovine erythrocytes which give a ... extracts prepared from sheep and horse ...
... available point-of-care diagnostic test that can reliably ... A and B. The test uses a ... that assists viral replication by promoting the ... The ZstatFlu substrate is labeled with a ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: